NEW DIGITAL INNOVATIONS AND IPSS-M COVERAGE LEAD TO INCREASE IN MDS HUB USERS

Press release: Available for immediate release

The MDS Hub, run by Scientific Education Support (SES) in partnership with the European LeukemiaNet (ELN), is an open-access online resource dedicated to providing balanced, reliable, and up-to-date medical education in myelodysplastic syndromes (MDS). During Q2 of 2022, the MDS Hub continued to share the latest advancements related to MDS, including updates from ongoing clinical trials and information on cutting-edge discoveries in treatments and therapeutic regimens.

In Q2 (April–June) of 2022, the hub recorded a number of expert discussions from our world-leading steering committee members, which covered some of the current hotly debated topics in MDS. These included the patient factors that should be considered beyond the Revised International Prognostic Scoring System (IPSS-R) and how to treat high-risk patients outside of a clinical trial. We also provided coverage of the new Molecular IPSS (IPSS-M) guidelines highlighting the differentiation between high-risk MDS and AML, the implications for the management of MDS, the flaws of existing risk-based scoring systems, and the most relevant genetic predictors of adverse and favorable outcomes.

Reviewing the MDS Hub’s impact this quarter, Claire Aukim-Hastie, Director of Scientific Services at Scientific Education Support, said:

“As part of our commitment to continuously enhance the hub user experience, we have recently introduced a new drug and trial update section on the MDS Hub, which provides users with the most recent drug and trial updates for their area of interest. This new functionality, which imports all updates directly from the hub’s Twitter account, means all drug and trial updates can be easily viewed and searched for in a single location.”

“The number of users visiting the hub this quarter reflects a strong performance so far this year, at just over 1,800; this is almost 73% more users than the same period of 2021. This provides us with a solid foundation on which to engage current users and attract more visitors to the hub during 2022.

“It is also extremely encouraging that the hub has reached 73 countries so far this year, 11 more when compared to the same period last year. This figure reflects the international reach of the hub’s activity and indicates that, on a global scale, our content is relevant and impactful.

“We would like to take this opportunity to show our gratitude for our expert steering committee, and existing supporters—Janssen Oncology, Bristol Myers Squibb, ThermoFisher Scientific—without whom this continued activity would not be possible.”

For more information on the MDS Hub, please visit mds-hub.com.

For media enquiries, or to explore collaboration opportunities, please contact or syndromes (MDS) refer to a group of hematopoietic disorders that result in the production of insufficient numbers of healthy blood cells, along with changes in bone marrow morphology and, eventually, overall failure of the bone marrow. Progression of MDS can be indolent or aggressive, and some patients may go on to develop acute myeloid leukemia.

The MDS Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education in MDS. Our aim is to enhance knowledge of MDS through the multichannel dissemination of global advances related to their classification, diagnosis, treatment, and management.

The MDS Hub shares new data, evidence-based articles, therapy approvals, expert opinions, and international congress coverage to treatment teams and researchers around the world. Informed by patients, curated by world leaders, and endorsed by expert societies, the MDS Hub supports HCPs worldwide.

Founded in partnership with the European LeukemiaNet (ELN) in 2020, the MDS Hub is guided by an international steering committee of experts in the field of MDS. The steering committee meet regularly to discuss the performance of the MDS Hub and to devise action plans on how best to support the MDS community and address any unmet educational needs.

Funding for our hubs is made possible through financial support from the pharmaceutical industry. All content is developed by SES in collaboration with an expert steering committee. All content is independent, and the educational supporters are allowed no influence on the content.

If you are interested in becoming an MDS Hub supporter, please contact is a medical education company with projects such as community physician education though our therapy hubs, community awareness and education through our ‘Know’ education initiatives, and academic researcher education through Entrepreneurs in Clinical Academia (ECA) programs.

Scientific Education Support already has a portfolio of successful websites supporting the advancement of medical education in the field of hemato-oncology: the ALL Hub, AML Hub, GvHD Hub, Lymphoma Hub, Multiple Myeloma Hub, and MPN Hub.

220 participating centers in 44 countries with more than 1000 researchers and clinicians are cooperating in the European LeukemiaNet. The objective is to integrate the about 120 leading leukemia trial groups (CML, AML, ALL, CLL, MDS, MPN), their interdisciplinary partner groups (diagnostics, treatment research, registry, guidelines), industry and SMEs across Europe to form a network promoting cooperative research for curing leukemia.